Method of treating neurotic personality development
SUBSTANCE: method involves a drug therapy with the antidepressant paroxetine in a daily dose of 40-50 mg a day in two stages daily for 30 days, the benzodiazepine anxiolytic diazepam 10-12 mg a day intramuscularly for 20 days, the antioxidant mexidol for the first 20 days intravenously drop-be-drop in a daily dose of 200-250 mg, and for the following 10 days in a dose of 375-400 mg orally in tablets, the immunocorrector Thymogen 0.01% in a dose of 1.2-1.3 ml intramuscularly once a day for 10 days followed by administering 1.2-1.3 ml intramuscularly every second day five times in a combination with hyperbaric oxygenation at excessive pressure 0.8-1.0 atm at compression and decompression rate 0.1 atm a minute with 40-minute isopressure from the first day of treatment for 21 days.
EFFECT: higher clinical effectiveness.
The invention relates to medicine, namely to psychiatry, and can be used in the treatment of patients with persistent forms of neurotic disorders - neurotic personality development, when the disease duration is five years or more.
A method of treating neurotic personality development using anxiolytics in combination with antidepressants, normotimicheskoe drugs and antipsychotic drugs, with mainly neuroleptic activity, - of thioxanthene derivatives, substituted benzamido, etc. For medicinal products traditionally used in the treatment of severe forms of neurotic disorders described many undesirable effects, such as side, manifested in the development of hematologic, endocrine, autonomic disorders, neurotic disorders, and toxic (Manual on psychiatry. In 2 volumes. Vol. 1/A. S. Tiganov, A. V. snezhnevsky, D. D. Orlovskaya, etc.; Under. Ed. A. S. Tiganov. - M.: Medicine, 1999. - S. 527-558).
With this method of treatment the risk of developing complications from therapy exceeds the clinical effect of drug combinations anxiolytics, normotimicheskoe drugs, antidepressants and neuroleptics. In addition, there is typically incomplete relief of symptoms, causes frequent� relapse, patients need long-term hospital treatment, which is associated with significant economic costs.
The technical result consists in the rapid and complete relief of leading with neurotic personality development of psychopathological symptoms and syndromes: deep stress due to neurotic disorders, combined with hypochondriacal fixation, depressive, conversion, obsessive - phobic manifestations in the case of the formation of obsessive - phobic and hysterical neurotic personality development, is due to the integrated effects of drug combinations cytoprotector, immunocorrector, anxiolytic, antidepressant, hyperbaric oxygen therapy on mental function, neuro-endocrine and immune homeostasis.
Said technical result is achieved in that in the method of treating neurotic personality development conducted pharmacotherapy simultaneously antidepressant paroxetine in a daily dose of 40-50 mg per day in two divided doses daily for 30 days, the benzodiazepine anxiolytic diazepam - 10-12 mg per day intramuscularly for 20 days, the antioxidant Mexidol initially intravenously in a daily dose of 200-250 mg the first 20 days and then in the next 10 days about 375-400 mg orally in tablets immunocorrector the timogen 0,01% a solution of 1.2-1.3 ml �nutramigen 1 time a day for 10 days followed by administration of 1.2-1.3 ml intramuscularly every other day, No. 5, in combination with hyperbaric oxygenation with a gauge pressure of 0.8-1.0 atmosphere, at a speed of compression and decompression of 0.1 atmospheres per minute, the period of isopress 40 minutes, 1 times a day for 21 days of treatment.
The method is carried out as follows. From the first day of treatment, patients are administered within 30 days: the antidepressant paroxetine inside 40-50 mg in two divided doses per day, benzodiazepine anxiolytic diazepam intramuscularly at 10-12 mg 1 time a day for 20 days, the antioxidant Mexidol initially intravenously in a daily dose of 200-250 mg in the first 20 days, then in the next 10 days the drug is given in pill in a daily dose of about 375-400 mg; immunocorrector timogen 0.01% solution administered by a 1.2-1.3 ml intramuscularly daily, 10 injections, then every other day for a 1.2-1.3 ml intramuscularly, 5 injections. At the same time during the first 21 days patients underwent hyperbaric oxygenation in single pressure chambers got 3-01 (NPF "LAD", Russia) with a gauge pressure of 0.8-1.0 atmosphere, at a speed of compression and decompression of 0.1 atmospheres per minute, the period of isopress is 40 minutes, 1 time per day.
Clinical example. Patient B., 42 years old, (case No. 2682), was treated in the Mordovian Republican psychiatric hospital (Saransk) with 08.12.2012, with a diagnosis of Neurotic personality development.
Did Sheikh�of psychiatrist city psychoneurological clinic with complaints of weakness, malaise, depressed mood, lack of desire to perform any activity, decreased appetite, sleep disturbances in the form of difficulty falling asleep and sleepiness during the day, decreased performance, unpleasant sensations in the body, changing from one section to another, in the form of tingling, twisting, burning.
From the anamnesis: the patient by nature anxious and insecure. At the end of 2005 on the background of long-term heavy stress situations, significant for the patient, there were complaints of weakness, malaise, depressed mood, lack of desire to perform any activity. Was repeatedly treated by a neurologist and psychiatrist as an outpatient. In 2012 joined hypochondriacal symptoms. The patient sought medical assistance in the city mental hospital, where he was sent for inpatient treatment in a psychiatric hospital.
Mental state at admission to hospital: Consciousness clear. Oriented to place, time, self correct. Her expression dull. Joined to the conversation on the issues. During the conversation often sighs, speech tempo is slow. Fixed on his painful condition, hard to switch to another topic of conversation. Expresses that after the experience of stressful situations (conflicts with her husband, infertility, divorce, Odie�the middle) appeared fatigue, weakness, malaise, lost the desire to perform any activity. Notes that the circle narrowed sharply ceased to meet and communicate with friends, to visit theatre and cinema. Notes reduced efficiency, there was a sense that not all meaning can understand, resulting in he quit his job. When the conversation periodically to eyes well up with tears, expressed complaints of painful unpleasant sensations in the body in the form of burning and tingling in different groups of muscles in different parts of the body moving from one place to another. Background mood is unstable with a predominance of anxious affect. Deception of perception is not revealed. Delusional ideas are not expressed. Criticism is reduced to a state.
The results of additional methods of research:
1. General analysis of blood from 08.12.2012, Hemoglobin 135 g/l, ESR - 8 mm/h, the total number of cells is 6.5×109/l: eosinophils - 2, stab neutrophils - 3, segmented - 67, lymphocytes - 26, monocytes - 2%. The General analysis of urine from 08.12.2012, without pathology.
2. The immunity from 08.12.2012, T-lymphocytes - 65%, lymphocytes 6%, and immunoglobulin M - 98 mg%, immunoglobulin G - 1150 mg%, immunoglobulin A - 118 mg%, phagocytosis activity of neutrophils is 69%, T-helpers - 39%, T-suppressor - 21%, circulating immune complexes: large - 0.e., medium - $ 15.e., small 104.e., adhesion of neutrophils to 16%, nst-test - 2%, an index of neutrophil activation is 0.01, the load index of 4.1.e., complementary activity of blood serum is 4.2. Conclusion: immunopathological condition - reducing the tension of the immune system functioning, weakening of humoral defense factors - hypoinsulinemia class A, lower total serum complement activity of blood, increasing small fraction of circulating immune complexes, decreased metabolic activity of neutrophils.
3. Hormonal status from 08.12.2012, Thyroid-stimulating hormone - 1.38 nmol/l, free thyroxine - 16,97 nmol/l, antibodies to thyroglobulin have been identified, the cortisol - 609,4 nmol/l increase in the concentration of cortisol in the blood serum.
For biochemical analysis of blood from 08.12.2012, pathological changes were found.
The diagnosis: Neurotic personality development.
1. Tab. Paroxetini 0,02
Orally 1 tablet 2 times a day for 30 days.
2. Sol. Diazepami 0,5% - 2 ml (10 mg)
Intramuscular injection of 10 mg 1 time per day, 20 days.
3. Sol. Mexidoli 5% - 4 ml (200 mg)
Sol. Natrii chloridi 0,9% - 400 ml
Intravenous drip, 1 times a day for 20 days.
Tab. Mexidoli 0,125
Inside: 1 tablet 3 times a day from 21 to 30 day.
4. Sol Thymogeni 0.01% to 1.2 ml
Intramuscularly 1 time a day, every day the first 10 days, with 11 days intramuscularly every other day 5 injek�rd.
5. Hyperbaric oxygen therapy, positive pressure of 0.8-1.0 atmosphere, at a speed of compression and decompression of 0.1 atmospheres per minute, the period of isopress - 40 minutes, 1 time per day during the first 21 days.
In the ongoing treatment: positive dynamics was observed, ranging from 10 days of treatment, quiet, questions answered after a pause, specified in the plan. In the Department of the research Institute became sociable, is actively involved in psychotherapeutic group sessions. Deception of perception, delusions are not identified. The orderly behavior. Thinking consistent, somewhat slowed the pace. Emotionally labile.
Mental status at the 20-day treatment: the patient calm, in the Department of communicative, engaged in a circle of patients. In touch takes on issues, responding on the merits. Correctly oriented in all types. Delusions, illusions of perception is not revealed. Notes an improvement in their condition in the form of normalization of sleep, appetite. Thinking consistent, somewhat slowed the pace. Background mood is closer to equal.
At the time of discharge (30-day): Consciousness clear. Oriented to place, time, self correct. Outwardly tidy. Contact for questions, answers specified in the plan. It consistent. Deception of perception, delusions are not revealed. Attention sustainable. The processes of remembering, FOTS�of otvedeniya not broken. Began to note that there is still interest in communication. Actively involved in rehabilitation activities. Makes plans about the need for job search and employment.
At discharge, the General blood and urine analysis, biochemical blood analysis - without pathological changes.
The immunity from 09.01.2013 G. T-lymphocytes - 65%, lymphocytes 6%, and immunoglobulin M - 112 mg%, immunoglobulin G - 1180 mg%, immunoglobulin A - 114 mg%, phagocytosis activity of neutrophils - 76%, T-helpers - 39%, T-suppressor - 9%, circulating immune complexes: large - 0.e., medium - 7 in.e., small - 35.e., adhesion of neutrophils to 18%, nst-test - 9%, an index of neutrophil activation - 0,09, the load index is 3.7.e., complementary activity of blood serum of 4.9. Conclusion: in comparison with immunological from 08.12.2012, there is a positive trend: to restore the functional activity of segmented neutrophils - increased NBT - test, an index of neutrophil activation, phagocytosis activity of neutrophils, normalized number of circulating immune complexes of the fine fraction recovered complementary activity of blood serum, the load index. Persists hypoinsulinemia class A.
Thus, in this clinical example, through the use of regimens with the use of Srednyaya�efticiency doses of antidepressant and anxiolytic on the background of the appointment of an antioxidant, immunocorrector, oxygen under high pressure were able to achieve significant clinical effect.
A method of treating neurotic personality development, consisting in the fact that conduct pharmacotherapy antidepressant paroxetine - 40-50 mg orally in two divided doses for 30 days, the benzodiazepine anxiolytic diazepam - 10-12 mg intramuscularly 1 time per day, 20 days, antioxidant Mexidol initially at a daily dose of 200-250 mg intravenously in the first 20 days, and then about 375-400 mg orally in tablets in the next 10 days, immunocorrector the timogen 0.01% solution of 1.2-1.3 ml intramuscularly daily in the amount of 10 injections, then 1.2-1.3 ml intramuscularly every other day in the amount of 5 injections, simultaneously with pharmacotherapy conduct hyperbaric oxygenation with a gauge pressure of 0.8-1.0 ATM at a speed of compression and decompression of 0.1 atmospheres per minute, the period of isopress is 40 minutes, in the first days of treatment 1 time per day for 21 days.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds of formula (I) and their pharmaceutically acceptable salts, wherein A is thiazolyl, oxazolyl, thienyl, furyl, imidazolyl, pyrazolyl or oxadiazolyl (structures of which are presented in cl.1 of the patent claim), R1 represents C1-6alkyl; R2 represents (i) phenyl substituted by halogen; C1-6alkyl optionally substituted by morpholine or C1-6dialkylamino; C1-6alkoxy optionally substituted by halogen; or heterocyclyl, wherein a heterocyclyl substitute is specified in morpholine; pyrazolyl optionally substituted by C1-6alkyl; piperidinyl; pyrrolidinyl; oxadiazolyl substituted by C1-6alkyl; furyl substituted by C1-6alkyl; dioxydoisothiazolidinyl; triazolyl; tetrazolyl substituted by C1-6alkyl, tridiazolyl substituted by C1-6alkyl; thiazolyl substituted by C1-6alkyl; pyridyl; or pyrazinyl; (ii) substituted or unsubstituted heterocyclyl specified in quinolinyl; pyridyl substituted by C1-6alkoxy or morpholinyl; or benzo [d] [1, 2, 3] triazolyl substituted by C1-6alkyl; R3 represents phenyl substituted by 2 or 3 substitutes specified in halogen; C1-6alkyl; C1-6alkoxy optionally substituted by halogen; hydroxy group; cyano; or -C(=O)ORa, wherein Ra represents phenyl; R4 represents hydrogen, C1-6alkyl or C1-6halogenalkyl. The invention also refers to a pharmaceutical composition containing the compounds of formula (I), a method for PDE10 inhibition, a method of treating neurological disorders, and to intermediate compounds: 2-(4-chlor-3,5-dimethoxyphenyl)furan and 4-(5-methyl-1,3,4-thiadiazol-2-yl)benzaldehyde.
EFFECT: compounds of formula (I) as PDE10 inhibitors.
39 cl, 13 ex, 2 tbl, 77 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a compound of structural formula (I), which possesses phosphodiesterase 10 inhibitory activity. In formula (I), R1 represents hydrogen, halogen or lower alkyl; the ring A represents optionally substituted 6-10-merous monocyclic or bicyclic heteroaryl containing 1 to 3 nitrogen atoms as heteroatoms, or a group containing a cycloaliphatic 6-merous ring condensed with the above heteroaryl, which is specified in 6-merous cycloalkane and aliphatic 6-merous heterocyclic ring containing an oxygen atom; the ring B represents optionally substituted 4-6-merous monocyclic nitrogen-containing group, which can additionally contain an oxygen atom or a 3-6-merous monocyclic hydrocarbonic group, which can be optionally saturated; R3 represents hydrogen; lower alkyl optionally substituted by a substitute specified in lower alkoxy; or lower cycloalky. The R2,Y radicals, as well as substitutes of the rings A and B are presented in the patent claim.
EFFECT: invention refers to the pharmaceutical composition containing the above compound, to a method of treating or preventing schizophrenia, anxiety disorders, drug addiction, disorders with a symptom of cognition deficiency, affective disorder or mood episode, each of which is mediated by phosphodiesterase 10 activity.
20 cl, 3 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and represents pharmaceutical compositions and oral dosage forms including granules prepared by wet granulation at a great shear force and containing an anhydrous crystalline (2R)-2-phenylcarbonyloxypropyl(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and C6-18 alkylsulphate. The invention also consists in methods of treating Parkinson's disease, schizophrenia, cognitive disorder, restless leg syndrome, periodic limb movement disorder, delayed dyskinesia, Huntington disease, hypertension and daytime sleepiness by administering a therapeutically effective amount of the pharmaceutical composition or dosage form into the patient.
EFFECT: controlling the formation of crystalline (2R)-2-phenylcarbonyloxypropyl(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate hydrate.
18 cl, 11 ex, 11 tbl, 9 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of organic chemistry, namely to compounds of N-phenyl(pyperazinyl or homopyperazinyl)benzenesulphonamide or benzenesulphonylphenyl(pyperazine or homopyperazine), or to their physiologically acceptable acid addition salts, described by general formulas (I) and (I'), where X is a chemical bond or a group N-R4; R1 is hydrogen or methyl; R2 is hydrogen or methyl; R3 is hydrogen, C1-C3alkyl, fluorine, C1-C2alkoxy or fluorinated C1-C2alkoxy; R4 is hydrogen, C1-C4alkyl or C3-C4cycloalkyl-CH2-; R5 is hydrogen, fluorine, chlorine, C1-C2alkyl, C1-C2alkoxy or fluorinated C1-C2alkoxy; R6 is hydrogen and n is 1 or 2. The invention also relates to a pharmaceutical composition based on the compound of formula
EFFECT: novel compounds, modulating activity of the 5HT6 receptor are obtained.
35 cl, 2 tbl, 105 ex
SUBSTANCE: invention discloses a method of preventing agglomeration of particles of an aripiprazole or 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butox]-1H-quinolin-2-one active ingredient in a suspension containing silicone oil and/or a silicone oil derivative in a dispersion medium, wherein the particle size of the active ingredient is 0.1-200 mcm. The method comprises mixing an active ingredient with silicone oil and/or silicone oil derivative in a dispersion medium such that the silicone oil and/or silicone oil derivative is contained in an amount of 0.001-0.2 pts.wt per 100 pts.wt of the active ingredient contained in the suspension. The invention also relates to a hardened composition for preparing a suspension administered by injection or orally.
EFFECT: preventing agglomeration of active ingredients in a suspension without special treatment.
9 cl, 4 tbl, 9 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds of formula
wherein R1 represents H, fluoro-, chloro- or C1-2alkoxygroup optionally substituted by one or more fluoro group; A represents O or S; R2 and R3 independently represent H or chloro; provided R2 and R3 are not positioned in relation to each other; R4 and R5 independently represent H or C1-4alkyl group; while X and Y independently represent O or CH2, provided X and Y are different. The invention also refers to a pharmaceutical composition possessing an antagonist activity in relation to type 1 melanin-concentrating hormone (MCH1) receptor and type 3 histamine receptor (H3) containing the compounds of formula I, a method of treating or preventing and to usage of the compounds of formula I.
EFFECT: compounds of formula I as type 1 melanin-concentrating hormone (MCH1) receptor and type 3 histamine receptor (H3) antagonists.
14 cl, 1 tbl, 2 dwg, 10 ex
SUBSTANCE: invention concerns an antipsychotic agent representing the amino acid glycine immobilised on the detonation-synthesised nanodiamond particles of 2-10 nm in size, and a method for preparing it.
EFFECT: higher efficacy of the agent, and improved method for preparing it.
4 cl, 5 dwg, 6 tbl, 3 ex
SUBSTANCE: invention relates to a compound of general formula I , where R1 is a hydrogen atom, a lower alkyl, CD3, -(CH2)n-CHO, -(CH2)n-O-lower alkyl, -(CH2)n-OH, -(CH2)n-cycloalkyl or is a heterocycloalkyl (where the heterocycloalkyl is a partially unsaturated ring containing up to 6 carbon atoms, at least one of which is substituted with O); R2 is a hydrogen atom, a halogen atom, hydroxy, lower alkyl, di-lower alkyl, -OCH2-O-lower alkyl or lower alkoxy; or the piperidine ring along with R2 forms a spiro-ring selected from 4-aza-spiro[2,5]oct-6-yl; Ar is an aryl or heteroaryl (where the heteroaryl is a cyclic aromatic hydrocarbon radical consisting of one ring and containing 6 ring atoms, and which contains at least one heteroatom selected from N), optionally having one, two or three substitutes selected from a halogen atom, lower alkyl, lower alkyl having as substitutes, a halogen atom, a lower alkoxy having as substitutes, a halogen atom, cycloalkyl, lower alkoxy, S-lower alkyl, heterocycloalkyl (where the heterocycloalkyl is a partially unsaturated ring containing up to 6 carbon atoms, at least one of which is substituted with N), or optionally having as substitutes, phenyl, optionally having R' as substitutes, and R' is a halogen atom, CF3, lower alkyl, lower alkoxy or a lower alkoxy having as substitutes, a halogen atom, or is a heteroaryl (where the heteroaryl is a cyclic aromatic hydrocarbon radical consisting of one ring and containing 6 ring atoms, and which contains at least one heteroatom selected from N and S); R is a lower alkyl, heterocycloalkyl (where the heterocycloalkyl is a partially unsaturated ring containing up to 6 carbon atoms, at least one of which is substituted with O), aryl or heteroaryl (where the heteroaryl is a cyclic aromatic hydrocarbon radical consisting of one ring and containing 6 ring atoms, and which contains at least one heteroatom selected from N), Where the aryl and heteroaryl optionally have as substitutes, one or two R'; n equals 0, 1, 2 or 3; or to a pharmaceutically acceptable acid addition salt, a racemic mixture or a corresponding enantiomer and/or optical isomer of said compound. The invention also relates to pharmaceutical compositions based on a glycine reuptake inhibitor of a compound of formula I.
EFFECT: obtaining novel compounds and a pharmaceutical composition based thereon, which can be used in medicine to treat neurological and psychoneurological disorders.
22 cl, 1 tbl, 128 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds possessing a high effectiveness in modulation of NMDA receptor activity.
EFFECT: compounds are applicable in treating the diseases and disorders, such as disturbed learning, cognitive activities, as well as for relieving and/or reducing neuropathic pain.
26 cl, 21 dwg, 2 tbl, 9 ex
SUBSTANCE: invention relates to N-[2,4-dioxo-6-(tetrahydrofuran-2-yl)-7-trifluoromethyl-1,4-dihydro-2H-quinazolin-3-yl]methanesulphonamide and N-[6-(1-isopropoxyethyl)-2,4-dioxo-7-trifluoromethyl-1,4-dihydro-2H- quinazolin-3-yl] methanesulphonamide, having antagonistic activity on the AMPA receptor. The invention also relates to a pharmaceutical composition.
EFFECT: use of said compounds to produce drugs for treating AMPA mediated conditions and primarily for treating epilepsy or schizophrenia.
6 cl, 81 ex
FIELD: medicine, psychiatry, neurology.
SUBSTANCE: method involves carrying out pharmacotherapeutic treatment for 20 days. Method involves treatment with mexidolum in the dose 150-200 mg per 24 h by intravenous drop route, diazepam in the dose 15-20 mg per 24 h by intramuscular route, immune correcting drug thymogenum in the dose 1 ml of 0.01% solution by intramuscular route, once per 24 h for the first 10 days and then five injections every other day by intramuscular route. Hyperbaric oxygenation under excessive pressure 0.8-1 atm at the rate compression and decompression 0.1 atm per a minute, isopression period for 40 min, 2 times per 24 h, is carried out with pharmacotherapy simultaneously. Invention provides rapid and stable reducing the main psychopathological symptoms: simple and complex motive tics and vocalism based on nonspecific complex normalizing effect on neurohomeostasis.
EFFECT: enhanced and valuable method of disease treatment.
FIELD: medicine, therapeutic stomatology.
SUBSTANCE: one should apply special medicinal preparations immobilized upon gelatin-glycerin splin, the foundation of which is presented as 28.57% gelatin, 17.86% glycerin and 53.57% water. Moreover, during the first 3 d one should apply malavit thrice daily after breakfast, dinner and before nocturnal period. Then, during 3 d patients should apply medicinal splints with trental in the morning, and before nocturnal sleeping - those with thymogenum, at final stage of therapy for 3 d it is necessary to use splints with collargol in the morning and before nocturnal sleeping. The innovation enables to interrupt inflammatory process efficiently and short period of time due to high-degree releasing of medicinal substances at strong fixation of the splints applied.
EFFECT: higher efficiency of therapy.
2 cl, 1 ex
FIELD: medicine, dermatology.
SUBSTANCE: method involves administration of an immunomodulator polyoxidonium or immunofan. In the case of patients with accompanying digestive tract diseases and after removal of papillomas of number below 50 polyoxidonium is administrated by the following schedule: by one suppository for 5 days at a time and by one suppository every other day. In the case of patients with the larger process incidence and with chronic tonsillitis immunofan is administrated is administrated by the following schedule: by 1 ml every other day (5 doses) and then 1 time, twice per a week (5 doses), and then 1 time per a week (5 doses). After the basic treatment course with immunomodulators the infusion of herbal species with immunomodulating properties is administrated of the following composition p.p.: buckthorn bark 60.0; peppermint leaves, 20.0; dandelion roots, 20.0; fennel and parsley fruits, by 20.0. Two table spoons of mixture is poured with two glasses of boiling water, boiled for 5 min, infused for 1 h and taken in the dose two glasses in morning before eating for 20 days. Also, preparation "Aevit" is given in the dose two capsules per a day for 3 weeks and treatment of accompanying diseases is carried out also. Method provides effectiveness of treatment and prophylaxis of relapses of skin pappilomas based on the complex effect on the immune system by immunomodulating preparations in combination with vegetable immunostimulators that prolong their effect. Invention can be used in treatment of skin papillomas.
EFFECT: improved method for prophylaxis.
1 tbl, 2 ex
FIELD: medicine, oncology.
SUBSTANCE: invention relates to a method for treatment of malignant tumors. Method involves administration in a patient the chemotherapeutically active dose of antitumor platinum compound, foe example, cisplatin or carboplatin and erythropoietin or erythropoietin-like substance wherein the latter is administrated before administration of platinum compound or simultaneously with its. This method provides attaining the synergistic antitumor effect.
EFFECT: improved and valuable medicinal effect.
8 cl, 2 tbl, 2 dwg, 2 ex
SUBSTANCE: invention relates to compound of formula:
double line between N and C represents double bond, X is absent, a Y stands for H; W stands for C=O; each of R1, R2, R3, R4 stands for H; R5 is selected from groups OR15, where R15 has the same determination as R; optionally R5 stands for binding group or is selected from groups: polypyrrole, polyindolyl, polyimidazolyle, polypyrrole-imidazolyle, polypyrrole-indolyl or polyimidazole-indolyl unit, optionally bound to binding groups; R6 stands for OR or optionally, R6 stands for binding group; Z is selected from groups (CH2)n, where n stands for 1, 2 or 3, CR15R16, where each of R15 and R16 independently stands for H or linear alkyl, having from 1 to 10 carbon atoms; R stands for H or linear or branched alkyl, having from 1 to 3 carbon atoms, optionally substituted with group -COR11; R11 stands for H or -OR14; and R14 stands for H or linear or branched alkyl, having from 1 to 3 carbon atoms; each of R1, R2, R3, R4, R1', R2', R3' and R4' stands for H, optionally any of R1, R2, R3, R4, R1', R2', R3' or R4' stands for binding group, Z is selected from groups (CH2)n, where n stands for 1, 2 or 3; R6 stands for OR, or optionally R6 stands for binding group; A and A′ stand for O, D and D', similar or different, and independently represent linear or branched alkyls, having from 1 to 10 carbon atoms; L is absent or stands for phenyl group, where said phenyl group representing L, is optionally substituted, where substituent is represented by binding group or is selected from OR7, NR8R9, NRCOR' or OCOR11; R and R' independently represent H or linear or branched alkyl, having from 1 to 10 carbon atoms, optionally substituted with halogen or group -COR7; R7, R8, R9 and R11 independently represent H or linear or branched alkyl, having from 1 to 10 carbon atoms, or polyethylene glycol unit (-OCH2CH2)n, where n stands for integer number from 1 to 10; on condition that said compound has not more than one binding group, which provides bond with cell-binding agent due to covalent bond, which possess anti-proliferative activity.
EFFECT: obtaining novel compounds.
24 cl, 59 dwg, 9 tbl, 40 ex
SUBSTANCE: 1-1.5 hours before the surgery, the selective β-adrenergic blocker Betaloc is injected in an amount of 0.3-0.5 ml subconjunctivally in an upper semi-circle of the eyeball in accordance with 10 to 2 o'clock of a clock face. Then, 30-40 minutes before the surgery, 50% analgin 2.0 ml, 1% dimedrol 1.0 ml, seduxen 2.0 ml are injected intramuscularly. The surgery is immediately preceded by a subtenon block with 2% naropin 1.5 ml.
EFFECT: method enables providing the more effective pre-surgical preparation by reducing an intraocular pressure in a combination with preventing systemic complications and postoperative inflammations.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the chemical-pharmaceutical industry and represents an orally disintegrating tablet composition, which includes particles of a therapeutic preparation, containing: a therapeutically effective quantity of, at least, one therapeutic preparation; 0.5-3% ODT binding polymer; sugar alcohol and/or saccharide; and a disintegrant, with particles of the therapeutic preparation being prepared by granulation of, at least, one therapeutic preparation, sugar alcohol and/or saccharide and the disintegrant in the presence of the ODT binding polymer, where the composition mainly disintegrates within approximately 30 seconds after contact with saliva in the oral cavity or in testing by a disintegration test <USP 701>.
EFFECT: drug form can be applied in elderly patients and patients with swallowing disorders.
28 cl, 8 dwg, 13 tbl, 5 ex
SUBSTANCE: what is involved is infusion therapy with crystalloid solutions at 15 ml/kg of a patient's body weight. That is followed by puncturing and catheterising an epidural space at the level of ThVII-ThVIII according to the standard practice and introducing a test dose of 2% lidocaine 3 ml. If observing no signs of intrathecal introduction of local anaesthetics 10 minutes later, a basic dose containing 0.75-1% naropin 10 ml or 0.25-0.5% marcaine 10 ml and clofelin 3-5 mcg/kg is introduced. Total intravenous anaesthesia follows 20 minutes after pre-medication with atropine 0.01 mg/kg, 1% diphenylhydramine 1 ml and relanium 10 mg and urethral catheterisation. A narcosis is induced with propofol in a dose of 2 mg/kg. Anaesthesia is maintained with propofol 2-4 mg/kg·h. After that, within the first hour following the detoxification, naloxone 12 mg is introduced intravenously; a naloxone measurement rate is supposed to make 0.8 mg/h for 4-5 following hours of general anaesthesia. The repeated introduction of 0.75-1% naropin 6 ml or 0.25-0.5% marcaine 6 ml and clofelin 2-3 mcg/kg into the epidural space is performed 90 minutes later. After the procedure is terminated, and the patient recovers, prolonged epidural analgesia is conducted by introducing 0.2% naropin 10 ml and clofelin 1 mcg/kg into the epidural space every 4 hours for 24-48 hours.
EFFECT: method provides safety of ultrafast opioid detoxification and prolongs the remission in the given category of patients.
SUBSTANCE: thoracic epidural analgesia is conducted by puncturing and catheterisation of an epidural space at ThVIII - ThIX before the expiry of 24 hours from the onset of a disease after a moderate intravenous infusion therapy in the amount of 15-20 mg/kg of crystalloid solutions. 20 minutes before an expected endoscopic papillosphincterotomy, a catheter is moved 4-5 cm in a cranial direction. At ThV-ThX, 0.4% naropin 10-12 ml or 0.2% Marcaine 10-12 ml and clonidine 100 mcg are administered through a catheter. That is followed by a pre-medication by administering 0.1% atropine 0.5-1 ml and 0.5% relanium 1-2 ml. Thereafter, the patient is taken to an X-ray operation room to conduct the endoscopic papillosphincterotomy without an endoscopic retrograde cholangiopancreatography with general pancreatic duct stenting. After the operation has been completed, the patient is taken to an intensive care unit wherein an extended epidural analgesia is conducted by administering 0.2% naropin 10-12 ml or 0.15% marcaine 10-12 ml into the epidural space every 4 hours until the patient is taken to a department of surgery.
EFFECT: early intestinal motility recovery, increased pancreatic secretion, prevented spasm of the gastrointestinal sphincter ensured by a pathological complete blockade of sympathetic impulsing.